SCHEMBL387329

SCHEMBL387329

[C]1=CCc2ccc(-c3ccccc3)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYRO3 Q06418 1/20 0.39
NTRK2 Q16620 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
TDP2 O95551 1/20 0.38
ALOX5 P09917 1/20 0.36
MEN1 O00255 3/20 0.36
MAPT P10636 3/20 0.36
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 2/20 0.36
GAA P10253 2/20 0.36
NPC1 O15118 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 3/20 0.35
ESR2 Q92731 3/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
ESR1 P03372 2/20 0.33
HSD17B10 Q99714 2/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383615 0.73 LTA4H (0.41) MEN1MAPTKMT2AGAANPC1
SCHEMBL29246 0.72
SCHEMBL7795183 0.69 AHR (0.37) PARP10KDM1A
SCHEMBL7790717 0.69 PNMT (0.34) TDP2ALDH1A1HSP90AA1ALOX15PARP10
SCHEMBL6253369 0.66 HSD17B3 (0.51) TYRO3NTRK2CLK4DYRK1BTDP2
SCHEMBL3136254 0.64 TDP2 (0.61) TYRO3NTRK2CLK4DYRK1BTDP2
SCHEMBL5713325 0.64 TDP2 (0.52) TYRO3NTRK2CLK4DYRK1BTDP2
SCHEMBL1482920 0.64 TDP2 (0.61) TYRO3NTRK2CLK4DYRK1BTDP2
SCHEMBL8085457 0.64 MEN1 (0.47) TDP2ALOX5MEN1MAPTKMT2A
SCHEMBL4895702 0.64 TYRO3 (0.53) TYRO3NTRK2CLK4DYRK1BTDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2007-06-21 US disclosed
US-20070105933-A1 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-05-10 US disclosed
EP-1300405-B1 AMINO ALCOHOL DERIVATIVES SANKYO CO (JP) 2007-04-18 EP disclosed
US-7199150-B2 Amino alcohol compounds SANKYO COMPANY, LIMITED (JP) 2007-04-03 US disclosed
US-6964976-B2 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2005-11-15 US disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed
US-20040132784-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2004-07-08 US disclosed
US-6723745-B2 PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL SANKYO COMPANY, LIMITED (JP) 2004-04-20 US disclosed
US-20030236297-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2003-12-25 US disclosed
EP-1300405-A1 AMINO ALCOHOL DERIVATIVES Sankyo Company, Limited (JP) 2003-04-09 EP disclosed
EP-1070703-A1 Cyclobutene derivatives Sankyo Company Limited (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236297-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A TYRO3 1956/4885NTRK2 3152/4885CLK4 4567/4885
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT TYRO3 1185/4885NTRK2 3456/4885CLK4 4485/4885
US-20040132784-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A TYRO3 1956/4885NTRK2 3152/4885CLK4 4567/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 TYRO3 105/4885NTRK2 3471/4885CLK4 3839/4885
US-20070105933-A1 Amino alcohol compounds ADH1C, C9, SSB TYRO3 522/4885NTRK2 1813/4885CLK4 4243/4885
US-20070142335-A1 Amino alcohol compounds or phosphonic acid derivatives thereof HRH3, C3AR1, HRH4 TYRO3 185/4885NTRK2 3947/4885CLK4 3318/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A TYRO3 674/4885NTRK2 3129/4885CLK4 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.